Moreover, we also found that PRDX4 was associated with multiple clinical characteristics, including age, sex, pathological subtype, lymph node metastasis, etc., suggesting that PRDX4 may be a potential prognostic marker for COAD. Here, PRDX4 is linked to metastatic malignant neoplasm in the lymph nodes.